EGFR and non-small cell lung carcinoma: In the FLAURA study, osimertnib achieved a median PFS of 18.9 months as a first-line treatment for NSCLC patients with drug-sensitive EGFR mutations, and the survival benefit was superior compared to that of first-generation EGFR-TKIs.